参一胶囊在NSCLC患者维持治疗中的疗效分析(1)
[摘要] 目的 探讨参一胶囊在非小细胞肺癌(NSCLC)患者维持治疗中的临床疗效。 方法 在该医院2017年9月—2018年9月期间诊治的NSCLC患者中方便选取40例作研究对象，均在放化疗后进行维持治疗;将放化疗后仅定期随访观察者设为对照组(n=20)，将在放化疗后应用参一胶囊进行维持治疗者设为研究组(n=20)，就2组患者维持治疗效果、炎症因子以及免疫功能变化进行统计学分析。 结果 ①研究组患者肿瘤控制率是55.0%，高于对照组的20.0%(χ2=5.227，P=0.22);②研究组患者治疗后的CD4+/CD8+水平高于对照组，而该组TNF-α水平均低于对照组(t=9.847、2.819，P=0.000、0.004)。 结论 参一胶囊在NSCLC患者维持治疗中的疗效显著，可改善肿瘤控制效果，促使TNF-α呈现低表达状态，并提高患者放化疗后免疫功能，值得借鉴。
[关键词] 参一胶囊;NSCLC;定期随访;免疫功能;维持治疗;肿瘤控制率;炎症因子
[中图分类号] R734.2 [文獻标识码] A [文章编号] 1674-0742(2019)05(b)-0103-03
[Abstract] Objective To investigate the clinical efficacy of Shenyi Capsule in the maintenance of non-small cell lung cancer (NSCLC) patients. Methods 40 patients with NSCLC who were treated in the hospital from September 2017 to September 2018 were convenient selected and enrolled in the study. All patients were treated with chemoradiotherapy. After radiotherapy and chemotherapy， only regular follow-up observations were used in the control group (n= 20)， after the use of chemoradiotherapy， the application of Shenyi capsule for maintenance treatment was set as the study group (n=20)， and the maintenance effect， inflammatory factors and immune function changes were statistically analyzed in the two groups. Results 1.The tumor control rate of the study group was 55.0%， which was higher than 20.0% of the control group (χ2=5.227， P=0.22). 2.The CD4+/CD8+ level of the study group was higher than that of the control group， and the TNF-α level of this group was lower than that of the control group (t=9.847， 2.819 P=0.000， 0.004). Conclusion Shenyi Capsule has a significant effect in the maintenance of NSCLC patients， which can improve the tumor control effect， promote the low expression status of TNF-α， and improve the immune function of patients after radiotherapy and chemotherapy. It is worth learning.
[Key words] Shenyi Capsule; NSCLC; Regular follow-up; Immune function; Maintenance therapy; Tumor control rate; Inflammatory factor
目前，临床上对于非小细胞肺癌(NSCLC)主要采取联合治疗方案，即对于有手术切除指征者，进行手术切除联合放化疗;而对于丧失手术治疗时机者，实施放化疗联合药物治疗，以加强对恶性肿瘤进展的控制[1]。其中，放化疗标准是先进行放射治疗，剂量是60～64 Gy，时间是6～7周，再进行4～6个周期的含铂双联方案化疗治疗，但放射治疗、化学治疗均可对消化系统、血液系统等带来副作用，损伤机体免疫功能，且部分患者在放化疗后4个月出现病情进展，导致不良预后。鉴于此，如何巩固放化疗效果、延迟肿瘤进展、提高患者带瘤生存期免疫功能以及生存质量，是肿瘤学领域的研究热点之一。近几年来，已有临床研究证明，放化疗后采取分子靶向药物治疗等在NSCLC维持治疗领域中的应用价值显著[2]。又有学者经研究证明，参一胶囊作为国内中草药中I类中药抗癌新药，联合放化疗用于NSCLC治疗中，可提高放化疗效果，并延长中位生存时间[3]，但该药品能否用作NSCLC放化疗后维持治疗中？对于NSCLC患者维持治疗效果、免疫功能有无辅助作用？为解决该问题，笔者开展了该次分组对照试验研究，对一组2017年9月—2018年9月期间诊治的、放化疗后非小细胞肺癌病例资料40例进行回顾性分析，现报道如下。, 百拇医药(徐道静)
[关键词] 参一胶囊;NSCLC;定期随访;免疫功能;维持治疗;肿瘤控制率;炎症因子
[中图分类号] R734.2 [文獻标识码] A [文章编号] 1674-0742(2019)05(b)-0103-03
[Abstract] Objective To investigate the clinical efficacy of Shenyi Capsule in the maintenance of non-small cell lung cancer (NSCLC) patients. Methods 40 patients with NSCLC who were treated in the hospital from September 2017 to September 2018 were convenient selected and enrolled in the study. All patients were treated with chemoradiotherapy. After radiotherapy and chemotherapy， only regular follow-up observations were used in the control group (n= 20)， after the use of chemoradiotherapy， the application of Shenyi capsule for maintenance treatment was set as the study group (n=20)， and the maintenance effect， inflammatory factors and immune function changes were statistically analyzed in the two groups. Results 1.The tumor control rate of the study group was 55.0%， which was higher than 20.0% of the control group (χ2=5.227， P=0.22). 2.The CD4+/CD8+ level of the study group was higher than that of the control group， and the TNF-α level of this group was lower than that of the control group (t=9.847， 2.819 P=0.000， 0.004). Conclusion Shenyi Capsule has a significant effect in the maintenance of NSCLC patients， which can improve the tumor control effect， promote the low expression status of TNF-α， and improve the immune function of patients after radiotherapy and chemotherapy. It is worth learning.
[Key words] Shenyi Capsule; NSCLC; Regular follow-up; Immune function; Maintenance therapy; Tumor control rate; Inflammatory factor
目前，临床上对于非小细胞肺癌(NSCLC)主要采取联合治疗方案，即对于有手术切除指征者，进行手术切除联合放化疗;而对于丧失手术治疗时机者，实施放化疗联合药物治疗，以加强对恶性肿瘤进展的控制[1]。其中，放化疗标准是先进行放射治疗，剂量是60～64 Gy，时间是6～7周，再进行4～6个周期的含铂双联方案化疗治疗，但放射治疗、化学治疗均可对消化系统、血液系统等带来副作用，损伤机体免疫功能，且部分患者在放化疗后4个月出现病情进展，导致不良预后。鉴于此，如何巩固放化疗效果、延迟肿瘤进展、提高患者带瘤生存期免疫功能以及生存质量，是肿瘤学领域的研究热点之一。近几年来，已有临床研究证明，放化疗后采取分子靶向药物治疗等在NSCLC维持治疗领域中的应用价值显著[2]。又有学者经研究证明，参一胶囊作为国内中草药中I类中药抗癌新药，联合放化疗用于NSCLC治疗中，可提高放化疗效果，并延长中位生存时间[3]，但该药品能否用作NSCLC放化疗后维持治疗中？对于NSCLC患者维持治疗效果、免疫功能有无辅助作用？为解决该问题，笔者开展了该次分组对照试验研究，对一组2017年9月—2018年9月期间诊治的、放化疗后非小细胞肺癌病例资料40例进行回顾性分析，现报道如下。, 百拇医药(徐道静)